CRISPR Therapeutics AG (CRSP) Stock Forecast
CRSP analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.91 / 5 from 23 analysts
- Price target
- $85.63 average of analyst targets
- Upside to target
- +73.9% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-1.07
- 52-week range
- $44.34 – $73.97
CRSP analyst ratings
23 analystsNumber of analysts at each rating.
CRSP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CRSP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.06 | −$1.50 | −$0.46 | −$1.17 | +9.4% | 17 |
| Current fiscal year (2026) | −$4.45 | −$5.84 | −$3.19 | −$6.47 | +31.3% | 19 |
| Next fiscal year (2027) | −$3.55 | −$5.40 | −$0.51 | −$4.45 | +20.1% | 19 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CRSP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $16.6M | $0 | $77.3M | +1,763.3% | 16 |
| Current fiscal year (2026) | $40.4M | $11.6M | $164.3M | +1,052.1% | 19 |
| Next fiscal year (2027) | $151.2M | $2.0M | $509.0M | +273.9% | 18 |
CRSP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CRSP revenue: reported and forecast
CRSP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.19 | −$1.06 | −$1.05 | −$1.05 | −$1.06 | −10.7% | 0 up · 1 down |
| Current fiscal year (2026) | −$4.88 | −$4.45 | −$4.45 | −$4.45 | −$4.45 | −8.9% | 0 up · 1 down |
| Next fiscal year (2027) | −$3.89 | −$3.50 | −$3.50 | −$3.52 | −$3.55 | −8.6% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CRSP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CRSP beat in 7 of 12.
What analysts expect from CRSP
23 analysts cover CRISPR Therapeutics; their consensus rating is buy (3.91 on a 1–5 scale, where 5 is a strong buy). The average price target is $85.63, 73.9% above the latest close of $49.25. Analysts expect earnings of −$4.45 per share for 2026, +31.3% from a year earlier. For 2027 the average estimate is −$3.55 per share on revenue of $151.2 million. CRISPR Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: CRSP income statement, CRSP key metrics, CRSP chart. See the CRSP stock overview for the latest quote and news.
CRSP forecast FAQ
What is CRISPR Therapeutics's price target?
The average analyst price target for CRISPR Therapeutics is $85.63, 73.9% above the latest close of $49.25.
Is CRISPR Therapeutics a buy, hold or sell?
Of 23 analysts covering CRISPR Therapeutics, 8 rate it a strong buy, 5 a buy, 10 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is CRISPR Therapeutics's EPS forecast?
Analysts forecast −$4.45 per share for 2026 (range −$5.84 to −$3.19); for 2027 the estimate is −$3.55.
What is CRISPR Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $40.4 million, growth of 1,052.1%; for 2027 it is $151.2 million.
When does CRISPR Therapeutics report earnings?
CRISPR Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-1.07.
Does CRISPR Therapeutics usually beat earnings estimates?
CRISPR Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.